Eli Lilly and MiNA Therapeutics to collaborate on saRNA research

pharmafile | May 12, 2021 | News story | Research and Development Eli Lilly 

Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform.

MiNA will utilise its saRNA platform, researching five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas.

Under the terms of the agreement, Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialisation rights for any products resulting from the collaboration.

Andrew C. Adams, PhD, Vice President for new therapeutic modalities at Lilly, said: “Small activating RNAs are a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue.

“We are excited about the potential of combining MiNA’s leading saRNA platform and our expertise in new modalities to accelerate development of RNA-based medicines in areas of high unmet medical need.”

MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialisation milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration.

Robert Habib, CEO of MiNA Therapeutics, said: “This collaboration with Lilly is an important validation of our saRNA platform. Lilly’s expertise in the field of RNA therapeutics and clinical development will greatly enhance our efforts to realise the technology’s full potential.

“Together, we aim to unlock new targets in multiple therapeutic areas and to ultimately move them towards clinical development and commercialisation.”

Kat Jenkins

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content